Sofosbuvir (GS-7977) Hepatitis C drug shows promise in late-stage trial

Hepatitis C drug shows promise in late-stage trial

Drug & Device Development

Last Updated: 2012-11-27 12:55:16 -0400 (Reuters Health)

(Reuters) - Gilead Sciences said a late-stage trial of its experimental hepatitis C treatment sofosbuvir showed that the virus was not detected in 78% of patients taking the drug, 12 weeks after completing therapy.

The trial named Positron tested sofosbuvir in patients who were unable or unwilling to take standard interferon therapy, which has unpleasant side effects.

No patient in the placebo group achieved an undetectable virus level 12 weeks after completing the therapy, Gilead said.

The safety profile of the drug was similar to that observed in prior studies, and there were few treatment discontinuations due to adverse events, Gilead said.

The company said it would submit the full data from the study for presentation at a scientific conference and will share data from additional late-stage studies in early 2013.

Gilead expects to submit its first regulatory filings for sofosbuvir by mid-2013, Chief Scientific Officer Norbert Bischofberger said.

Copyright © 2012 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Copyright 2012 Thomson Reuters. Click for Restrictions.